PD-1 antibody monotherapy for malignant melanoma: A systematic review and meta-analysis

30Citations
Citations of this article
72Readers
Mendeley users who have this article in their library.

Abstract

Antibodies targeting programmed death 1 (PD-1) help prevent tumor cells from escaping immune-mediated destruction. We conducted this systematic review and meta-analysis to gain insight into the efficacy of PD-1 antibodies for the treatment of melanoma. Five trials involving 2,828 adult patients were included in this meta-analysis. In patients with previously untreated or refractory melanoma, treatment with PD-1 antibodies significantly improved the six-month progression-free survival (PFS) (HR 0.55, 95% CI 0.50-0.60, P<0.00001) and the overall response rate (OR 3.89, 95% CI 3.12-4.83, P<0.00001). This meta-analysis indicated that anti-PD-1 treatment might provide a significant survival benefit in patients with melanoma. In addition, we found that patients treated with nivolumab reported significantly fewer treatment-related adverse events (OR 0.74, 95% CI 0.57-0.97, P = 0.03) than those treated with other agents, but there was a dose-dependent increase in the frequency of adverse events in patients treated with pembrolizumab.

Cite

CITATION STYLE

APA

Lin, Z., Chen, X., Li, Z., Luo, Y., Fang, Z., Xu, B., & Han, M. (2016). PD-1 antibody monotherapy for malignant melanoma: A systematic review and meta-analysis. PLoS ONE, 11(8). https://doi.org/10.1371/journal.pone.0160485

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free